



PARIS, 22 SEPTEMBER 2014

AMS refinances its debt and continues its development with the acquisition of ASDIA



The AMS group, a comprehensive provider of medical-technical home services, continues its development and strengthens its position in the field of insulin therapy with the acquisition of ASDIA from the CeeD (Centre Européen d'Etude du Diabète).

For the past six years, Capzanine has been an active supporter of AMS (Assistances Médicales Spécialisés), a provider of home healthcare services, specialising in medical equipment that is specific to respiratory illnesses, insulin therapy and perfusion. With a network of 18 agencies spread across the whole country, AMS has 300 employees and a portfolio of over 15,000 customers. The merger with ASDIA, specialised in medical-technical home services in the field of insulin therapy and CPAP (continuous positive airway pressure) respiratory support, will enable AMS to continue its development and strengthen its position in this market segment. In this transaction, Capzanine underwrote the full financing in the form of unitranche debt which reimburse the existing debt and finance the ASDIA acquisition. The two entities will represent a consolidated pro forma turnover of €55m

Previously, in the AMS takeover in 2008, Capzanine had taken a majority shareholding stake alongside the management. In 2011, after several years of growth and reorganisation of the company, Capzanine sold its shares to LBO Partners, the new majority shareholder. Since then, in December 2013, the company has continued to develop through external growth, in particular in the PNI (perfusion, nutrition, insulin therapy) business lines with the acquisition of Alternative, a company based in Lyons and specialised in perfusion.

Guillaume de Jongh, Principal at CAPZANINE declared:

“We are very pleased to continue to support AMS and LBO Partners in their development strategy and we are confident in the capacity of management to continue to grow while maintaining the quality of the services provided to patients, which is the AMS trademark.”

About Capzanine...

Founded in 2004, Capzanine is an independent investment fund and a pioneer in combined equity and mezzanine investment. It supports businesses in their quest for growth, providing financial and industrial expertise to help them successfully achieve their development and transfer phases. Depending on the circumstances, Capzanine invests as a majority or minority shareholder and/or as a mezzanine provider in small and mid-cap companies with an enterprise value of 20 million to 300 million euros. Based in Paris and run by its partners, Capzanine currently has € 920 million in assets under management. Its portfolio includes companies such as DGF, Compagnie de Vichy, Opteven, Neoxam, Groupe Star's Service, Le Béliet, Nexeya...

More information: www.capzanine.com